Evidence map›Paper›PMID 35289062›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.

Tobias Frischmuth, Kristian Hindberg, Pål Aukrust, Thor Ueland, Sigrid K Braekkan, John-Bjarne Hansen, Vânia M Morelli

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Tobias FrischmuthThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0003-3203-3686
Kristian HindbergThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Pål AukrustThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Thor UelandThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0001-5005-0784
Sigrid K BraekkanThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-9678-9696
John-Bjarne HansenThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Vânia M MorelliThrombosis Research Center, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-0872-6645
University Hospital of North Norway · NOOslo University Hospital · NOThrombosis Research Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated with VTE remains uncertain.

objectiveTo investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity.

methodsA population-based nested case-control study, comprising 383 VTE cases and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort. PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across PAI-1 tertiles.

resultsThe VTE risk increased dose-dependently across PAI-1 tertiles (P for trend <.001) in the age- and sex-adjusted model. The OR of VTE for the highest versus lowest tertile was 1.73 (95% CI 1.27-2.35), and risk estimates were only slightly attenuated with additional stepwise adjustment for body mass index (BMI; OR 1.59, 95% CI 1.16-2.17) and C-reactive protein (CRP; OR 1.54, 95% CI 1.13-2.11). Similar results were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. In obese subjects (BMI of ≥30 kg/m

conclusionOur findings indicate that plasma PAI-1 is associated with increased risk of future incident VTE and has the potential to partially mediate the VTE risk in obesity.

Indexed as

Venous ThromboembolismCase-Control StudiesC-Reactive ProteinHumansObesityPlasminogen Activator Inhibitor 1Risk FactorsC-Reactive ProteinPlasminogen Activator Inhibitor 1deep vein thrombosisfibrinolysisobesityplasminogen activator inhibitor 1pulmonary embolismvenous thromboembolism

Identifiers

PMID35289062
PMCPMC9314992
OpenAlexW4220672779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.